Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 22, 2011 Matt Koppenheffer	Could Eli Lilly's Stock Double Your Money? With concerns swirling around the big pharma companies, could it be time to buy Eli Lilly?
The Motley Fool June 6, 2011 Matt Koppenheffer	Could Medtronic Double Your Money? Is it high time to add Medtronic's stock to your portfolio?
The Motley Fool June 30, 2011 Matt Koppenheffer	Could National Presto Double Your Money? Is it high time to add this stock to your portfolio?
The Motley Fool June 26, 2011 Matt Koppenheffer	Could Google Score You 100% Returns? Is it high time to add Google's stock to your portfolio?
The Motley Fool March 17, 2011 Matt Koppenheffer	Could Raytheon's Stock Double? Could defense giant Raytheon be a path to 100% returns?
The Motley Fool March 9, 2011 Matt Koppenheffer	Could Wal-Mart's Stock Double? Can Wal-Mart's stock double? Under the upside scenario, the answer is a very definite "yes."
The Motley Fool July 11, 2011 Matt Koppenheffer	Waste Management Ain't No Garbage Stock Is it high time to add this thrifty trash hauler's stock to your portfolio?
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
The Motley Fool April 12, 2011 Matt Koppenheffer	Could Intel Score You 100% Returns? Could chip champ Intel be your ticket to 100% returns?
The Motley Fool August 24, 2011 Matt Koppenheffer	Could PepsiCo's Stock Double Your Money? In a tumultuous market, is PepsiCo your ticket to big returns?
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool May 18, 2011 Jordan DiPietro	Should You Buy and Hold Teva Pharmaceutical? The Israeli pharma firm passes all four of our retirement portfolio tests.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool August 23, 2010 Jordan DiPietro	How Safe Are Eli Lilly's Dividends? Check out how Eli Lilly stacks up
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool August 30, 2010 Ilan Moscovitz	Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool August 4, 2010 Matt Koppenheffer	How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale?
The Motley Fool December 13, 2011	A Brief History of Teva Pharmaceutical's Returns The good news is that, at 15 times earnings, Teva shares now look reasonably valued.
The Motley Fool February 24, 2011 Jordan DiPietro	Should You Retire With Merck? Is Merck a good choice for a retirement portfolio?
The Motley Fool October 22, 2010 Anand Chokkavelu	7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool November 29, 2010 Seth Jayson	Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Abbott Laboratories Is Attractive? The company meets all the criteria above, and it could offer a 14% return over time -- although it will be hard for the company to maintain such a dividend growth rate.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool January 15, 2008 Brian Orelli	Fewer Generics in Fido's Future TEVA considers selling its small animal-health business.
The Motley Fool May 24, 2011 Andrew Tonner	Does Eli Lilly Deserve a Spot in Your Portfolio? A quick check of the numbers should help get us started.
The Motley Fool August 10, 2010 Jim Mueller	3 Beaten-Down Dividend Payers A look at three companies that might deserve a spot in your portfolio.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool February 25, 2011 Todd Wenning	Dividend Report Card: Bristol-Myers Squibb How does the pharma giant's dividend stack up?
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.